Is RFS up or down today?
RFS is down 0.48% today, last at 136.43. This stock moved -0.48% versus the prior close.
RFS · RFS
RFS (RFS) is trading at 136.43, down 0.48% on the session. RFS sits at the 50% mark of its 52-week range.
Leading the coverage: “Rajasthan govt transfers 69 IFS officers, promotes 22 RFS officers to IFS - Business Standard” (Google News Company, 33d ago). RFS is -6.44% since story.
RFS trades on a trailing P/E of 14.3.
Analyst firms are mostly reiterating — no strong directional shift lately.
RFS is down 0.48% today, last at 136.43. This stock moved -0.48% versus the prior close.
Leading the coverage: “Rajasthan govt transfers 69 IFS officers, promotes 22 RFS officers to IFS - Business Standard” (Google News Company, 33d ago). RFS is -6.44% since story. Dominant story: mRNA Vaccine Plus Pembrolizumab Yields RFS, DMFS Benefit in Melanoma - Targeted Oncology (1 source, neutral) RSI unavailable Price sits at 50% of its 52-week range Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Historical price chart unavailable
Live quote in the header is real, but OHLC history could not be loaded from Yahoo Finance or fallback providers. Charts use Yahoo when configured correctly — check server logs for provider errors.
mRNA Vaccine Plus Pembrolizumab Yields RFS, DMFS Benefit in Melanoma - Targeted Oncology
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma - OncLive
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melano - Business Wire
Rajasthan govt transfers 69 IFS officers, promotes 22 RFS officers to IFS - Business Standard
AFPM files legal challenge against RFS ‘Set 2’ rule - Ethanol Producer Magazine